Hu Zheyi, Zhou Zaigang, Hu Yahui, Wu Jinhui, Li Yunman, Huang Wenlong
State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Nanjing, 210009, China.
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210093, China.
PLoS One. 2015 Feb 17;10(2):e0116886. doi: 10.1371/journal.pone.0116886. eCollection 2015.
Multidrug efflux transporter P-glycoprotein (P-gp) is highly expressed on membrane of tumor cells and is implicated in resistance to tumor chemotherapy. HZ08 is synthesized and studied in order to find a novel P-gp inhibitor.
MDCK-MDR1 monolayer transport, calcein-AM P-gp inhibition and P-gp ATPase assays were used to confirm the P-gp inhibition capability of HZ08. Furthermore, KB-WT and KB-VCR cells were used to evaluate the P-gp inhibitory activity of HZ08 both in vitro and in vivo.
Results showed that HZ08 was more potent than verapamil in MDCK-MDR1 monolayer transportation model. Meanwhile, P-gp ATPase assay and calcein-AM P-gp inhibition assay confirmed that HZ08 inhibited P-gp ATPase with a calcein-AM IC50 of 2.44±0.31μM. In addition, significantly greater in vitro multidrug resistance reversing effects were observed when vincristine or paclitaxel was used in combination with 10μM HZ08 compared with 10μM verapamil. Moreover, HZ08 could significantly enhance the sensitivity of vincristine with a similar effect like verapamil in both KB-WT and KB-VCR tumor xenograft models.
The novel structure HZ08 could be a potent P-gp inhibitor.
多药外排转运体P-糖蛋白(P-gp)在肿瘤细胞膜上高度表达,与肿瘤化疗耐药有关。合成并研究了HZ08以寻找新型P-gp抑制剂。
采用MDCK-MDR1单层转运、钙黄绿素-AM P-gp抑制及P-gp ATP酶测定来确认HZ08的P-gp抑制能力。此外,使用KB-WT和KB-VCR细胞在体外和体内评估HZ08的P-gp抑制活性。
结果表明,在MDCK-MDR1单层转运模型中,HZ08比维拉帕米更有效。同时,P-gp ATP酶测定和钙黄绿素-AM P-gp抑制测定证实,HZ08抑制P-gp ATP酶,钙黄绿素-AM的IC50为2.44±0.31μM。此外,与10μM维拉帕米相比,当长春新碱或紫杉醇与10μM HZ08联合使用时,观察到显著更强的体外多药耐药逆转作用。此外,在KB-WT和KB-VCR肿瘤异种移植模型中,HZ08能显著增强长春新碱的敏感性,其效果与维拉帕米相似。
新型结构的HZ08可能是一种有效的P-gp抑制剂。